$MBRX

PICKER DONALD H purchased 173,333 shares of MBRX

PICKER DONALD H (Chief Science Officer) purchased 173,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Original reporting
SEC EDGAR · PICKER DONALD H
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MBRX
Bullish
low confidence
Mentioned
$MBRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MBRXBullishLow
01

Why it matters

The newest fact is the CSO’s open-market purchase of 173,333 shares (dated 2026-08-03) reported on 2026-08-05.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new clinical, regulatory, or financial information.

03

What to watch

No 10b5-1 plan and no disclosed transaction price/value, so the signal strength is weaker than a large, priced buy tied to a clear thesis.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Moleculin Biotech, Inc.

Company-level read

Ticker impact

$MBRXBullishLow confidence
Context

Form 4 shows Moleculin Biotech CSO Picker Donald H bought 173,333 shares on 2026-08-03, increasing direct holdings to 174,086.

Expected impact

Low to modest positive bias for sentiment; limited impact on fundamentals unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the price is not disclosed and there is no accompanying operational or financial update.

Market effects

Minimal. Single insider purchase in a biotech does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine diversification or planned liquidity needs, especially without disclosed price or context.

Key entities

  • Moleculin Biotech, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Picker Donald H

    Chief Science Officer who executed the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MBRXMed

Moleculin Biotech completes enrollment in AML trial phase

Moleculin Biotech (MBRX) completed enrollment in Part A of its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed/refractory acute myeloid leukemia. Interim efficacy results were reported, with full data expected in Q1 2027. The company plans to proceed with Part B and seeks additional financing for trials. Annamycin is also being developed for soft tissue sarcoma lung metastases.

$MBRXHighAI 8/10

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Moleculin Biotech (MBRX) released a CEO Corner segment discussing progress in its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory AML. Enrollment in Part A is complete, with interim results showing promise. Full data is expected in Q1 2027. The company also outlined plans for Part B expansion and broader applications for Annamycin.

$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto